[{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Eversana","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Maralixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eversana \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eversana \/ Mirum Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Maralixibat

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioTrinity 2025
                          Not Confirmed
                          BioTrinity 2025
                          Not Confirmed

                          Details : Under the terms of the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan. Takeda will also be responsible for development, including conducting clinical studies in cholestatic indications.

                          Product Name : LUM001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 21, 2021

                          Lead Product(s) : Maralixibat

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Mirum Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          BioTrinity 2025
                          Not Confirmed
                          BioTrinity 2025
                          Not Confirmed

                          Details : Mirum will utilize EVERSANA’s commercialization platform to provide integrated nationwide distribution, specialty pharmacy, patient services and Hub support for maralixibat, if approved.

                          Product Name : LUM001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 15, 2020

                          Lead Product(s) : Maralixibat

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Mirum Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank